diet pill news
W8loss Reviews
HOME
Diet News
Health Canada Reports
Archive



HOME > Weight Loss Reviews News > Diet News > Orexigen(R) Therapeutics Announces Completion Of Patient Enrollment In Phase III Clinical Program For Contrave(R)

Orexigen(R) Therapeutics Announces Completion Of Patient Enrollment In Phase III Clinical Program For Contrave(R)





Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-303 and NB-304, the final two Phase III clinical trials for Contrave®, its lead obesity product candidate. Today's announcement marks the completion of patient enrollment for the full Contrave Phase III program, keeping Contrave on track for an NDA submission to the FDA in late 2009.




Zend - is SUXX